ProCE Banner Activity

DLL3: Bringing Bispecific Therapy to SCLC

Clinical Thought

Read this commentary on targeting DLL3 with an investigational bispecific therapy for patients with previously treated SCLC.

Released: May 11, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This activity is supported by educational funding provided by Amgen.

Amgen

Target Audience

This educational program is intended for medical oncologists and other healthcare professionals who care for patients with SCLC.

Disclosure

Primary Author

Ticiana Leal, MD

Associate Professor
Department of Hematology & Oncology
Director, Thoracic Medical Oncology
Medical Director, Clinical Trials Office
Winship Cancer Institute
Emory University
Vice-President/President-Elect
Georgia Society of Clinical Oncology
Atlanta, Georgia

Ticiana Leal, MD: consultant/advisor/speaker: AstraZeneca, Catalyst, DSI, Eisai, EMD Serono, Janssen, Jazz, Lilly, Merck, Mirati, Novocure, Regeneron, Roche, Takeda.